Back

Don’t stop at statins: complementary PCSK9 use in patients at high risk for recurrent cardiac events

European Heart Journal - Quality of Care and Clinical Outcomes

3 April 2019
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis
1 September 2025
thumbnail
Congress Presentation
Forging the path: strategic combinations to achieve lipid targets
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources